You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2025

GLUCOTROL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Glucotrol, and when can generic versions of Glucotrol launch?

Glucotrol is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in GLUCOTROL is glipizide. There are eighteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the glipizide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Glucotrol

A generic version of GLUCOTROL was approved as glipizide by AUROBINDO PHARMA USA on May 10th, 1994.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GLUCOTROL?
  • What are the global sales for GLUCOTROL?
  • What is Average Wholesale Price for GLUCOTROL?
Summary for GLUCOTROL
US Patents:0
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 123
Clinical Trials: 15
Patent Applications: 4,270
Drug Prices: Drug price information for GLUCOTROL
What excipients (inactive ingredients) are in GLUCOTROL?GLUCOTROL excipients list
DailyMed Link:GLUCOTROL at DailyMed
Drug patent expirations by year for GLUCOTROL
Drug Prices for GLUCOTROL

See drug prices for GLUCOTROL

Recent Clinical Trials for GLUCOTROL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Memorial Sloan Kettering Cancer CenterPhase 2
Baylor College of MedicinePhase 4
NovartisPhase 2

See all GLUCOTROL clinical trials

US Patents and Regulatory Information for GLUCOTROL

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-001 May 8, 1984 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-002 May 8, 1984 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-003 May 11, 1993 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-002 Apr 26, 1994 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-003 Aug 10, 1999 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries

Expired US Patents for GLUCOTROL

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-001 May 8, 1984 ⤷  Subscribe ⤷  Subscribe
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-002 May 8, 1984 ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 2 of 2 entries

International Patents for GLUCOTROL

See the table below for patents covering GLUCOTROL around the world.

CountryPatent NumberTitleEstimated Expiration
Austria 305305 ⤷  Subscribe
Malaysia 7300007 NEW PYRAZINE DERIVATIVE ⤷  Subscribe
Netherlands 6915776 ⤷  Subscribe
Switzerland 547809 VERFAHREN ZUR HERSTELLUNG VON PYRAZINDERIVATEN. ⤷  Subscribe
Yugoslavia 33931 ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 5 of 5 entries

GLUCOTROL Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Glucotrol (Glipizide)

Market Definition and Overview

Glucotrol, known generically as glipizide, is a medication belonging to the class of sulfonylureas. It is used to treat high blood sugar levels caused by type 2 diabetes by stimulating the release of insulin from the pancreas[2].

Market Size and Forecast

The global sulfonylureas market, which includes glipizide, is anticipated to grow significantly over the forecast period. As of 2021, the sulfonylureas market was valued at USD 6,600.44 million and is expected to reach USD 8,485.43 million by 2029, registering a CAGR of 3.19% from 2022 to 2029[1].

Key Drivers of Market Growth

Rising Prevalence of Type 2 Diabetes

The increasing prevalence of type 2 diabetes globally is a major driver for the growth of the sulfonylureas market. According to the World Health Organization, approximately 1.9 billion adults were overweight in 2016, with around 650 million being obese, which are significant risk factors for diabetes[1].

Increasing Healthcare Expenditure

Rising healthcare expenditure and improvements in healthcare infrastructure also contribute to the market's growth. Government initiatives to enhance healthcare infrastructure through increased funding further support this trend[1].

Growing Geriatric Population

The increasing geriatric population is another significant factor. Older individuals are more prone to type 2 diabetes, which increases the demand for sulfonylureas like glipizide[1].

Market Segments and Distribution Channels

The sulfonylureas market, including glipizide, is segmented by drugs (Glyburide, Glipizide, Glimepiride, Others), indication (Diabetes, Others), dosage form (Tablets, Capsules, Others), route of administration (Oral, Others), end-users (Hospitals, Specialty Clinics, Homecare, Others), and distribution channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)[1].

Geographical Market Analysis

North America

North America dominates the sulfonylureas market due to the presence of major key players and high healthcare expenditure. The increasing prevalence of diabetes in this region further propels market growth[1].

Asia-Pacific

The Asia-Pacific region is expected to grow significantly during the forecast period due to a surging population and growing awareness about diabetes. Improvements in healthcare infrastructure and government initiatives in this region also contribute to market growth[1].

Product Overview and Mechanism of Action

Glipizide, marketed as Glucotrol, works by stimulating the release of insulin from the pancreas, helping to lower blood sugar levels and restore the body's ability to use food for energy. It is available in various dosage forms, including tablets and extended-release tablets[2].

Clinical Use and Precautions

Glipizide is prescribed for managing type 2 diabetes and is often used in conjunction with diet and other medications. However, it is not recommended for patients with type 1 diabetes or diabetic ketoacidosis. Patients with certain medical conditions, such as heart or blood vessel disease, kidney or liver disease, and G6PD deficiency, should use glipizide with caution[2].

Side Effects and Monitoring

Regular monitoring by healthcare professionals is crucial to ensure the proper functioning of glipizide. Common side effects include indigestion, passing gas, and more severe effects like low blood sugar, anxiety, and blurred vision. Patients must report any unwanted effects to their healthcare provider promptly[2].

Financial Performance and Sales History

Historically, Glucotrol has been a significant contributor to the antidiabetic market. For example, in 1985, worldwide sales of Glucotrol reached $30 million, despite overall declines in Pfizer's antidiabetic product sales due to generic competition[5].

Current Market Trends and Future Outlook

The global glipizide market is expected to continue growing, driven by the increasing demand for effective diabetes management. New product launches and advancements in drug formulations, such as oral GLP-1s, may also influence the market dynamics, although glipizide remains a staple due to its generic availability and established efficacy[4].

Research and Development Opportunities

The market's growth is also fueled by an increase in research and development activities. New and more efficient diabetic treatments and monitoring products are being developed, which will further boost the market's growth rate. Emerging markets and advancements in technology will provide additional opportunities for the sulfonylureas market, including glipizide[1].

Challenges and Restraints

Despite the growth potential, the market faces challenges such as competition from newer diabetes treatments like GLP-1 drugs, which have shown significant health benefits beyond weight loss and diabetes management[3]. Additionally, pricing strategies and supply chain issues can impact market dynamics.

Key Takeaways

  • The sulfonylureas market, including glipizide, is driven by the rising prevalence of type 2 diabetes and increasing healthcare expenditure.
  • The market is segmented by various factors, including drugs, indications, dosage forms, and distribution channels.
  • North America and Asia-Pacific are key regions driving market growth.
  • Glipizide is a crucial medication for managing type 2 diabetes but comes with specific precautions and potential side effects.
  • The market is expected to grow, influenced by research and development, despite facing competition from newer treatments.

FAQs

What is Glucotrol used for?

Glucotrol, or glipizide, is used to treat high blood sugar levels caused by type 2 diabetes by stimulating the release of insulin from the pancreas[2].

What are the common side effects of Glucotrol?

Common side effects include indigestion, passing gas, and more severe effects like low blood sugar, anxiety, and blurred vision[2].

How does Glucotrol compare to other diabetes treatments?

Glucotrol is part of the sulfonylureas class, which is different from newer treatments like GLP-1 drugs. While it remains effective, newer treatments have shown additional health benefits beyond diabetes management[3].

What are the key drivers of the sulfonylureas market growth?

The key drivers include the rising prevalence of type 2 diabetes, increasing healthcare expenditure, and the growing geriatric population[1].

What is the forecasted market size for the sulfonylureas market?

The sulfonylureas market is expected to reach USD 8,485.43 million by 2029, registering a CAGR of 3.19% from 2022 to 2029[1].

Cited Sources:

  1. Data Bridge Market Research - Global Sulfonylureas Market - Industry Trends and Forecast to 2029.
  2. Mayo Clinic - Glipizide (oral route).
  3. Goldman Sachs - Weighing the GLP-1 market.
  4. Mobility Foresights - Global Glipizide Market 2024-2030.
  5. Citeline Insights - PFIZER's ANTI-DIABETIC GLUCOTROL WORLDWIDE SALES.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.